Alzheimer’s disease, the most common form of dementia, is a progressive neurological disease that affects memory, thinking and independence. Today, more than 55 million people worldwide are living with dementia, with Alzheimer’s disease accounting for an estimated 60–70% of cases.¹

The onset and progression of Alzheimer’s disease involve complex biology and multiple pathological drivers, including amyloid beta and tau proteins.²

Amyloid beta can accumulate in the brain and form plaques that are believed to contribute to the disease process.² Tau proteins normally help support healthy neuron function. Neurons transmit information throughout the body but when they become abnormal with a buildup of beta-amyloid plaques outside the neuron and tau protein tangles inside the neuron, the transmissions are blocked and can contribute to neurodegeneration and cognitive decline.³

Alzheimer’s disease is usually diagnosed in people aged 65 years and older, but it may start earlier, with subtle neurological changes occurring years or even decades before symptoms appear. Many people may experience early, often unrecognized signs of mild cognitive impairment before receiving a diagnosis.

Driven by our commitment to patients and our deep expertise in neuroscience, we are advancing Alzheimer’s disease innovation by relentlessly following the science and targeting key drivers of the disease. We aim to help address unmet needs in this devastating condition, with an emphasis on earlier diagnosis, intervention and treatment.

Amyloid pathology can begin decades before symptoms appear and may contribute to downstream tau pathology, which is thought to be closely linked to neuronal dysfunction and clinical decline.^3,4 Recognizing this complexity, we believe advancing innovation in Alzheimer’s disease will require personalized, multimodal approaches that address multiple drivers of disease biology.

We understand how incredibly challenging it is to treat this complex and progressive condition, which is why we will never stop innovating for patients, families and providers in the Alzheimer’s disease community. 

We are advancing research to support earlier diagnosis through blood-based biomarkers and investigating therapies directed at key drivers of Alzheimer’s disease biology, including amyloid and tau. By deepening our understanding of these distinct but interconnected pathways, we aim to help address the complexity of Alzheimer’s disease and advance innovation across the disease continuum.

We are currently conducting clinical trials to evaluate the efficacy and safety of investigational drugs in our pipeline for people living with Alzheimer’s disease.